1443679-20-6

Basic information

• Product Name: O₇-nitrooxyethyl luteolin
• Synonyms: O₇-nitrooxyethyl luteolin
• CAS NO: 1443679-20-6
• Molecular Weight: 375.292
• Mol File: 1443679-20-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: O₇-nitrooxyethyl luteolin(CAS DataBase Reference)
• NIST Chemistry Reference: O₇-nitrooxyethyl luteolin(1443679-20-6)
• EPA Substance Registry System: O₇-nitrooxyethyl luteolin(1443679-20-6)

Safety Data

• Hazardous Substances Data: 1443679-20-6(Hazardous Substances Data)

Upstream product

• 491-70-3 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-on 
• 1443679-17-1 O₇-nitrooxyethyl-O₃',O₄'-diphenylmethane luteolin 
• 1443679-14-8 O₇-bromethyl-O₃',O₄'-diphenylmethane luteolin 
• 1201808-21-0 2-(2,2-diphenyl-1,3-benzodioxol-5-yl)-5,7-dihydroxy-4H-1-benzopyran-4-one 

Relevant articles and documents

Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors

Aldose reductase (AR) plays an important role in the design of drugs that prevent and treat diabetic complications. Aldose reductase inhibitors (ARIs) have received significant attentions as potent therapeutic drugs. Based on combination principles, three series of luteolin derivatives were synthesised and evaluated for their AR inhibitory activity and nitric oxide (NO)-releasing capacity in vitro. Eighteen compounds were found to be potent ARIs with IC 50 values ranging from (0.099 ± 0.008) μM to (2.833 ± 0.102) μM. O7-Nitrooxyethyl-O3′,O 4′-ethylidene luteolin (La1) showed the most potent AR inhibitory activity [IC50 = (0.099 ± 0.008) μM]. All organic nitrate derivatives released low concentrations of NO in the presence of l-cysteine. Structure-activity relationship studies suggested that introduction of an NO donor, protection of the catechol structure, and the ether chain of a 2-carbon spacer as a coupling chain on the luteolin scaffold all help increase the AR inhibitory activity of the resulting compound. This class of NO-donor luteolin derivatives as efficient ARIs offer a new concept for the development and design of new drug for preventive and therapeutic drugs for diabetic complications.